|drug2451||Placebo (Methylcellulose) capsule Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
Description: SurvivalMeasure: Survival without need of mechanical ventilation Time: Day 14 since symptom onset
Description: WHO Progression ScaleMeasure: WHO progression scale ≤ 5 at day 4 since admission. Time: Score on day 4 since admission
Description: Successful tracheal extubationMeasure: Cumulative incidence of successful tracheal extubation at day 14 since symptom onset. Time: Day 14 since symptom onset
Description: WHO Progression ScaleMeasure: WHO progression scale ≤ 7 at day 4 since admission. Time: Score on day 7 since admission
Description: SurvivalMeasure: Survival at day 14 of hospitalization Time: Day 14
Description: Duration of hospitalizationMeasure: Duration of hospitalization Time: Day 28
Description: Time to hospital dischargeMeasure: Time to hospital discharge Time: Day 28
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports